AUROBINDO PHARMA LTD.

NSE : AUROPHARMABSE : 524804ISIN CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse : Aurobindo
BSE767.90-10.4 (-1.34 %)
PREV CLOSE ( ) 778.30
OPEN PRICE ( ) 778.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 150091
TODAY'S LOW / HIGH ( )764.60 785.40
52 WK LOW / HIGH ( )281.15 819.55
NSE767.90-9.95 (-1.28 %)
PREV CLOSE( ) 777.85
OPEN PRICE ( ) 777.85
BID PRICE (QTY) 767.90 (122)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2204399
TODAY'S LOW / HIGH( ) 764.50 786.60
52 WK LOW / HIGH ( )288.85 819.75
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 26-12 1986
Management Info
K Ragunathan - Chairman N Govindarajan - Managing Director
Registered Office

Address Plot No. 2,Maitrivihar ,Ameerpet,
Hyderabad,
Telangana-500038

Phone +91-040-66725000

Email info@aurobindo.com

Website www.aurobindo.com

Registrars Details
K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS
25Jun Aurobindo Pharma developing range of p
Aurobindo Pharma is developing a range of products including 14 biosimil..
23Jun M&M, Maruti Suzuki and Karnataka Bank
Mahindra & Mahindra (M&M) has introduced its new Sarpanch Plus r..
23Jun Aurobindo Pharma jumps on planning to
Aurobindo Pharma is currently trading at Rs. 810.00, up by 23.60 points..
22Jun Aurobindo Pharma planning to launch 50
Aurobindo Pharma is planning to launch 50 to 60 new products in US in FY..
04May Aurobindo Pharma gets USFDA’s nod for
Aurobindo Pharma has received final approval from the US Food and Drug A..
Financials
Rs. in Millions
QTR Mar 20 ANNUAL 20
Net Profit7250.418727.4
Gross Profit 8728.9 23777
Operating Profit 1009229437.6
Net Sales 36203.2132664.8
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Procter&Gamble Healt (BSE)
 4254.45 (4.65%)
M.Cap (Rs. in Cr)7062.12
Abbott India (BSE)
 15730.90 (0.44%)
M.Cap (Rs. in Cr)33427.06
Valiant Organics (BSE)
 1713.60 (3.85%)
M.Cap (Rs. in Cr)2081.89
Aarti Drugs (BSE)
 1321.55 (3.77%)
M.Cap (Rs. in Cr)3079.21
Natco Pharma (BSE)
 691.20 (4.25%)
M.Cap (Rs. in Cr)12584.54
Shareholding Pattern
PROMOTERS 52.01%
NON-INSTITUTION 13.16%
MUTUAL FUNDS/UTI 11.95%
FI/BANKS/INSURANCE 0.61%
GOVERNMENT 0%
FII 0%
ATTENTION INVESTORSKYCIPO
Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do’s & Don’t’s) in Vernacular Language :
REGISTRATION NOS.

NSE CM-INZ000234235|NSE F& O - INZ000234235, NSE CD-INZ000234235, BSE CM–INZ000234235 |BSE F & O - INZ000234235|BSE CD- INZ000234235 MCX-SX CM-INZ000234235|MCX-SX F & O - INZ000234235|MCX-SX CD-INZ000234235 NSDL - IN-DP-NSDL-319-2009ROC REG - 21-097912,CDSL : IN-DP-242-2016

INVESTOR PROTECTION

Compliance officer : Sanjay Jadli, Apurva Mittal, Tel No: 022-40790035,022-40790024, Mobile No: 9152943075,9768009000, E-mail ID: compliance@nnmsecurities.com,cdsl@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

Filing complaints on SCORES Easy & quick

  • > Register on SCORES portal
  • > Mandatory details for filing complaints on SCORES
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • > Benefits:
    • Effective communication
    • Speedy redressal of the grievances

For Lodge the grievances click on https://scores.gov.in

Click/visit on SEBI Complaints Redress System (SCORES) for Procedure for filing of complaints on SCORES and benefits.

Copyright © 2016 NNM Securities.com

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.